Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
39.68
-1.53 (-3.71%)
At close: Jan 2, 2026, 4:00 PM EST
39.97
+0.29 (0.73%)
After-hours: Jan 2, 2026, 7:25 PM EST
Dianthus Therapeutics Revenue
Dianthus Therapeutics had revenue of $396.00K in the quarter ending September 30, 2025, a decrease of -81.77%. This brings the company's revenue in the last twelve months to $3.08M, down -42.64% year-over-year. In the year 2024, Dianthus Therapeutics had annual revenue of $6.24M with 120.63% growth.
Revenue (ttm)
$3.08M
Revenue Growth
-42.64%
P/S Ratio
552.74
Revenue / Employee
$39,462
Employees
78
Market Cap
1.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.24M | 3.41M | 120.63% |
| Dec 31, 2023 | 2.83M | -3.59M | -55.96% |
| Dec 31, 2022 | 6.42M | 4.94M | 334.76% |
| Dec 31, 2021 | 1.48M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionDNTH News
- 10 days ago - Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) - GlobeNewsWire
- 5 weeks ago - Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 2 months ago - Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results - GlobeNewsWire
- 2 months ago - Dianthus Therapeutics to Participate in Four Investor Conferences During November - GlobeNewsWire
- 2 months ago - Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting - GlobeNewsWire
- 2 months ago - Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases - GlobeNewsWire
- 3 months ago - Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting - GlobeNewsWire
- 4 months ago - Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire